Trial Profile
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ibrutinib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2023 Results for safety and feasibility, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 08 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 10 Mar 2022 Planned End Date changed from 1 Feb 2022 to 1 Mar 2026.